Medical Device Network on MSN
Hims & Hers Health signs agreement to acquire YourBio Health
The transaction closure is anticipated in early 2026, contingent on regulatory approvals and other customary conditions.
Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...
Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...
What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, ...
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Hims & Hers Health, Inc. (HIMS) reports results for the quarter ended September 2025. While this widely-known ...
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback